Spots Global Cancer Trial Database for A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
Official Title: Prospective, Open, Multi-center, Double Arm Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
Study ID: NCT02779569
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and clinical efficacy of ultra-low-dose decitabine in Chinese MDS
Detailed Description: To develop a highly effective and safe protocol, a multi-center, prospective clinical trial was conducted in China, with aims to evaluate the grade III and IV hematologic toxicity and clinical efficacy of subcutaneous injection of ultra-low-dose decitabine (5 to 7 mg/m2) for treatment of myelodysplastic syndrome (MDS), while decitabine at a dose of 20 mg/m2 as a control.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
No.303 Hospital of Chinese People's Liberation Army, Nanning, Guangxi, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Shengjing Hospital of China Medical Univercity, Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China
Zhejiang Provincial Hospital of TCM, Hangzhou, Zhejiang, China
Contact Details
Name: Guangsheng He
Affiliation: The First Affiliated Hospital with Nanjing Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
